symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RGLS,1.29,1.647384,35626,25135005,0,0.76-2.14,0.03,Regulus Therapeutics Inc.,USD,0001505512,US75915K3095,75915K309,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.regulusrx.com,"Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.",Mr. Joseph P. Hagan M.B.A.,Healthcare,US,30,858 202 6300,4224 Campus Point Court,San Diego,CA,92121,0.903719,2.37372,https://financialmodelingprep.com/image-stock/RGLS.png,2012-10-09,False,False,True,False,False
